{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"502"}],"units":"Participants"}],"description":"An AE is defined as \"any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment\". An AE can therefore be any unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as nausea or chest pain), an abnormal laboratory finding (including results of blood tests, x-rays or scans) or a disease temporarily associated with the use of the protocol treatment, whether or not considered related to the investigational medicinal product. The number of participants who discontinued study treatment due to an AE was reported for all participants in each treatment arm.","groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.","id":"OG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants in Part 1 who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 22 months","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}